Fractyl Health, Inc. (NASDAQ:GUTS) Stock Has Consensus Price Target of $50.25

Shares of Fractyl Health, Inc. (NASDAQ:GUTS) have been given an average rating of “Hold” by the five analysts that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $50.25.

Several brokerages recently weighed in on GUTS. Wall Street Zen downgraded shares of Fractyl Health from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings cut Fractyl Health from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 3rd. Craig Hallum set a $5.00 target price on Fractyl Health in a research note on Monday, October 19th. Finally, Morgan Stanley cut their target price on Fractyl Health to $4.00 and set an “equal weight” rating on the stock in a research note on Monday, October 19th.

Fractyl Health Stock Up 8.7%

Shares of Fractyl Health stock opened at $0.88 on Friday. The company has a quick ratio of 3.15, a current ratio of 3.15 and a debt-to-equity ratio of 1.41. Fractyl Health has a 52-week low of $0.80 and a 52-week high of $29.34. The company has a 50-day simple moving average of $4.19 and a two-hundred day simple moving average of $7.12.

Fractyl Health (NASDAQ:GUTS) last issued its earnings results on Monday, August 10th. The company reported ($1.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.62) by $0.18. Equities research analysts forecast that Fractyl Health will post -5.88 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Sanctuary Advisors LLC bought a new stake in Fractyl Health in the 2nd quarter worth about $26,000. Private Advisor Group LLC purchased a new position in Fractyl Health in the 3rd quarter worth about $27,000. Accredited Investors Inc. purchased a new position in Fractyl Health in the 1st quarter worth about $46,000. FNY Investment Advisers LLC lifted its stake in Fractyl Health by 84.3% during the 2nd quarter. FNY Investment Advisers LLC now owns 65,420 shares of the company’s stock valued at $51,000 after acquiring an additional 29,920 shares during the period. Finally, PEAK6 LLC bought a new position in Fractyl Health during the 2nd quarter valued at about $159,000.

About Fractyl Health

Fractyl Health, Inc. is a biotechnology company focused on developing therapies for metabolic diseases, including obesity and type 2 diabetes. The company aims to create treatments that address the underlying biology of these conditions and provide longer-lasting alternatives to frequently administered medicines. Fractyl Health’s technology platforms include Revita, an endoscopic procedure designed to modify the lining of the duodenum and potentially improve metabolic function, and a gene therapy platform intended to enable the body to produce therapeutic levels of metabolic hormones such as glucagon-like peptide-1 (GLP-1).